Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that its Phase 3 Aspire study of apazunersen (GTX-102) in Angelman syndrome failed to meet ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE